Hologic (HOLX) Q3 Revenue Beats 1%
(NASDAQ:HOLX), a global medical technology company specializing in diagnostics and women’s health, reported financial results for the third quarter of fiscal 2025 on July 30, 2025. The most notable headline: both GAAP revenue and non-GAAP earnings per share came in ahead of expectations, with GAAP revenue at $1,023.8 million compared to the $1,008.6 million analyst consensus, and non-GAAP earnings per share of $1.08 versus the $1.06 forecast. These figures beat both external analyst and company guidance (non-GAAP). The company continued to generate strong operating cash flow, though Organic revenue growth and margins faced headwinds in certain segments, particularly in Breast Health. Overall, Hologic posted a mixed quarter with clear outperforming areas, but underlying pressure in some key markets and business lines.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Hologic is a leading developer and manufacturer of medical devices and diagnostic products, with a core focus on women’s health. Its main business segments are Diagnostics, Breast Health, Surgical, and Skeletal Health.
Source Fool.com
